Last reviewed · How we verify
Propranolol and etodolac
This combination uses propranolol (a beta-blocker) to reduce heart rate and blood pressure, and etodolac (an NSAID) to reduce inflammation and pain.
This combination uses propranolol (a beta-blocker) to reduce heart rate and blood pressure, and etodolac (an NSAID) to reduce inflammation and pain. Used for Phase 3 investigational indication (specific indication not publicly disclosed).
At a glance
| Generic name | Propranolol and etodolac |
|---|---|
| Also known as | Deralin and etopan |
| Sponsor | Assaf-Harofeh Medical Center |
| Drug class | Beta-blocker and NSAID combination |
| Target | Beta-adrenergic receptors (propranolol); COX-1 and COX-2 (etodolac) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular and Pain/Inflammation |
| Phase | Phase 3 |
Mechanism of action
Propranolol blocks beta-adrenergic receptors, decreasing cardiac output and sympathetic nervous system activity. Etodolac inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain. The combination may be investigated for conditions where both cardiovascular modulation and anti-inflammatory effects are therapeutically beneficial.
Approved indications
- Phase 3 investigational indication (specific indication not publicly disclosed)
Common side effects
- Fatigue
- Dizziness
- Gastrointestinal upset
- Bradycardia
- Hypotension
Key clinical trials
- Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression (PHASE2)
- A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) (NA)
- Perioperative Intervention to Reduce Metastatic Processes in Pancreatic Cancer Patients Undergoing Curative Surgery (PHASE2)
- Colorectal Metastasis Prevention International Trial 2 (PHASE2)
- Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer (PHASE2)
- Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC) (PHASE2)
- Perioperative Administration of COX 2 Inhibitors and Beta Blockers to Women Undergoing Breast Cancer Surgery (NA)
- β-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Propranolol and etodolac CI brief — competitive landscape report
- Propranolol and etodolac updates RSS · CI watch RSS
- Assaf-Harofeh Medical Center portfolio CI